Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.

Abstract: The invention relates to syringes for storing and mixing components.

Abstract: The invention relates to syringes for storing and mixing components.

Abstract: The present inventions are directed to spray tips for multidirectional or three-dimensional spraying of an unmixed two-part sealant and/or hemostat comprising a first biocompatible component and a biocompatible second component onto a tissue or wound comprising: a hollow body having inside a first component distribution compartment and a second component distribution compartment, said compartments not in fluid communication with each other. The first component can contain one or more biologic components, preferably fibrinogen and the second component can contain one or more biologic component different from the first biologic component, preferably thrombin and/or thrombin precursors. The present inventions are also directed to methods of spraying the unmixed two-part sealant or hemostat using the spray tip and associated components described above by simultaneously expressing the first component and the second component from the syringes.

Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL and wherein PEG-SG portion is composed of a blend of 2 PEG-SG different in arm number or arm lengths.

Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Abstract: The present inventions are directed to spray tips for multidirectional or three-dimensional spraying of an unmixed two-part sealant and/or hemostat comprising a first biocompatible component and a biocompatible second component onto a tissue or wound comprising: a hollow body having inside a first component distribution compartment and a second component distribution compartment, said compartments not in fluid communication with each other. The first component can contain one or more biologic components, preferably fibrinogen and the second component can contain one or more biologic component different from the first biologic component, preferably thrombin and/or thrombin precursors. The present inventions are also directed to methods of spraying the unmixed two-part sealant or hemostat using the spray tip and associated components described above by simultaneously expressing the first component and the second component from the syringes.

Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Abstract: The invention relates to syringes for storing and mixing components.

Abstract: The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade.

Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.